These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
466 related articles for article (PubMed ID: 28296140)
1. Inhibitors of STAT3, β-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors. Merino VF; Cho S; Liang X; Park S; Jin K; Chen Q; Pan D; Zahnow CA; Rein AR; Sukumar S Mol Oncol; 2017 May; 11(5):552-566. PubMed ID: 28296140 [TBL] [Abstract][Full Text] [Related]
2. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling. Young CD; Pfefferle AD; Owens P; Kuba MG; Rexer BN; Balko JM; Sánchez V; Cheng H; Perou CM; Zhao JJ; Cook RS; Arteaga CL Cancer Res; 2013 Jul; 73(13):4075-85. PubMed ID: 23633485 [TBL] [Abstract][Full Text] [Related]
3. Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA Cheng F; Zhao J; Hanker AB; Brewer MR; Arteaga CL; Zhao Z Breast Cancer Res Treat; 2016 Dec; 160(3):457-474. PubMed ID: 27771839 [TBL] [Abstract][Full Text] [Related]
5. PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling. Cheng H; Liu P; Ohlson C; Xu E; Symonds L; Isabella A; Muller WJ; Lin NU; Krop IE; Roberts TM; Winer EP; Arteaga CL; Zhao JJ Oncogene; 2016 Jun; 35(23):2961-70. PubMed ID: 26640141 [TBL] [Abstract][Full Text] [Related]
6. Cooperation between Pik3ca and p53 mutations in mouse mammary tumor formation. Adams JR; Xu K; Liu JC; Agamez NM; Loch AJ; Wong RG; Wang W; Wright KL; Lane TF; Zacksenhaus E; Egan SE Cancer Res; 2011 Apr; 71(7):2706-17. PubMed ID: 21324922 [TBL] [Abstract][Full Text] [Related]
7. PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation. Liu S; Tang Y; Yan M; Jiang W Invest New Drugs; 2018 Oct; 36(5):763-772. PubMed ID: 29504069 [TBL] [Abstract][Full Text] [Related]
8. Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Hanker AB; Pfefferle AD; Balko JM; Kuba MG; Young CD; Sánchez V; Sutton CR; Cheng H; Perou CM; Zhao JJ; Cook RS; Arteaga CL Proc Natl Acad Sci U S A; 2013 Aug; 110(35):14372-7. PubMed ID: 23940356 [TBL] [Abstract][Full Text] [Related]
9. Activation of WNT/β-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations. Park YL; Kim HP; Cho YW; Min DW; Cheon SK; Lim YJ; Song SH; Kim SJ; Han SW; Park KJ; Kim TY Int J Cancer; 2019 Jan; 144(2):389-401. PubMed ID: 29978469 [TBL] [Abstract][Full Text] [Related]
10. The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in Ippen FM; Alvarez-Breckenridge CA; Kuter BM; Fink AL; Bihun IV; Lastrapes M; Penson T; Schmidt SP; Wojtkiewicz GR; Ning J; Subramanian M; Giobbie-Hurder A; Martinez-Lage M; Carter SL; Cahill DP; Wakimoto H; Brastianos PK Clin Cancer Res; 2019 Jun; 25(11):3374-3383. PubMed ID: 30796030 [TBL] [Abstract][Full Text] [Related]
11. Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells. Arjumand W; Merry CD; Wang C; Saba E; McIntyre JB; Fang S; Kornaga E; Ghatage P; Doll CM; Lees-Miller SP Oncotarget; 2016 Dec; 7(50):82424-82439. PubMed ID: 27489350 [TBL] [Abstract][Full Text] [Related]
12. Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA. Garay JP; Smith R; Devlin K; Hollern DP; Liby T; Liu M; Boddapati S; Watson SS; Esch A; Zheng T; Thompson W; Babcock D; Kwon S; Chin K; Heiser L; Gray JW; Korkola JE Breast Cancer Res; 2021 Aug; 23(1):81. PubMed ID: 34344439 [TBL] [Abstract][Full Text] [Related]
13. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers. Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061 [TBL] [Abstract][Full Text] [Related]
14. PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models. Nisa L; Häfliger P; Poliaková M; Giger R; Francica P; Aebersold DM; Charles RP; Zimmer Y; Medová M Mol Cancer; 2017 May; 16(1):93. PubMed ID: 28532501 [TBL] [Abstract][Full Text] [Related]
15. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Kataoka Y; Mukohara T; Shimada H; Saijo N; Hirai M; Minami H Ann Oncol; 2010 Feb; 21(2):255-262. PubMed ID: 19633047 [TBL] [Abstract][Full Text] [Related]
16. Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors. Meyer DS; Brinkhaus H; Müller U; Müller M; Cardiff RD; Bentires-Alj M Cancer Res; 2011 Jul; 71(13):4344-51. PubMed ID: 21482677 [TBL] [Abstract][Full Text] [Related]
17. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Lehmann BD; Bauer JA; Schafer JM; Pendleton CS; Tang L; Johnson KC; Chen X; Balko JM; Gómez H; Arteaga CL; Mills GB; Sanders ME; Pietenpol JA Breast Cancer Res; 2014 Aug; 16(4):406. PubMed ID: 25103565 [TBL] [Abstract][Full Text] [Related]
18. Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer. Young CD; Zimmerman LJ; Hoshino D; Formisano L; Hanker AB; Gatza ML; Morrison MM; Moore PD; Whitwell CA; Dave B; Stricker T; Bhola NE; Silva GO; Patel P; Brantley-Sieders DM; Levin M; Horiates M; Palma NA; Wang K; Stephens PJ; Perou CM; Weaver AM; O'Shaughnessy JA; Chang JC; Park BH; Liebler DC; Cook RS; Arteaga CL Mol Cell Proteomics; 2015 Jul; 14(7):1959-76. PubMed ID: 25953087 [TBL] [Abstract][Full Text] [Related]
19. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers. Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759 [TBL] [Abstract][Full Text] [Related]
20. Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer. Yang W; Hosford SR; Dillon LM; Shee K; Liu SC; Bean JR; Salphati L; Pang J; Zhang X; Nannini MA; Demidenko E; Bates D; Lewis LD; Marotti JD; Eastman AR; Miller TW Clin Cancer Res; 2016 May; 22(9):2250-60. PubMed ID: 26733612 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]